ABT - Diabetes device stocks gain after Abbott CEO downplays GLP-1 threat
2023-10-18 14:54:09 ET
More on Abbott Laboratories, DexCom, etc.
- Abbott Laboratories (ABT) Q3 2023 Earnings Call Transcript
- Abbott Laboratories Triumphs Over Challenges: A Tale Of Resilience
- Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income
- Abbott beats in Q3 despite post-COVID headwinds to diagnostics
- Abbott Laboratories Non-GAAP EPS of $1.14 beats by $0.04, revenue of $10.14B beats by $320M
For further details see:
Diabetes device stocks gain after Abbott CEO downplays GLP-1 threat